linjc16/ctgov huggingface dataset:
Retrospective Study of the Protective Effect of Gastrodin on Myocardium in Patients Undergoing Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Retrospective collection of Wuhan Union hospital from December 1,2018 to June 30,2021 to meet the entry and discharge standards. The patient 's medical record data were divided into study group and control group according to the use of gastrodin during operation. The perioperative data and prognostic outcomes in the patient 's medical records were collected and analyzed. The degree of myocardial injury and postoperative clinical outcomes were compared between the two groups.

Official Title
-----------------
Retrospective Study of the Protective Effect of Gastrodin on Myocardium in Patients Undergoing Cardiac Surgery

Conditions
-----------------
Cardiac Surgical Procedures

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged≥18 years, regardless of gender; Patients undergoing elective cardiac surgery under general anesthesia; ASA grade 1   3. Exclusion Criteria: Suffering from more serious genetic diseases (such as immunodeficiency, thalassemia, etc.); Moderate to severe malnutrition, moderate to severe anemia; Persistent infection; Severe preoperative underlying diseases (such as severe liver and kidney dysfunction)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GAS<br> | |
| Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The degree of myocardial injury | The myocardial tissue trimmed by the surgeon according to the surgical requirements was collected during the operation for electron microscopy observation and detection of related molecular content. | The myocardial tissue was collected during the operation. About 2 hours on average |
HRV Biofeedback to Treat Ulcerative Colitis

Study Overview
=================
Brief Summary
-----------------
This is a prospective interventional study exploring the modifiability of physiological metrics, namely HRV, using a 5-week standardized HRV biofeedback intervention in subjects with symptomatic ulcerative colitis. Participants will be followed for 17 weeks. The goal is the understand if modifying these markers can impact ulcerative colitis related symptoms.

Official Title
-----------------
Heart Rate Variability Biofeedback in the Treatment of Ulcerative Colitis

Conditions
-----------------
Ulcerative Colitis

Intervention / Treatment
-----------------
* Behavioral: HRV biofeedback


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult subjects (18-65 years old) Ulcerative colitis with a symptomatic flare (SCCAI ≥3) and without inflammation (FC<250µg/ml) Exclusion Criteria: Individuals who take medications known to alter heart rate variability Individuals with pacemakers or other implantable devices

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HRV biofeedback<br>An HRV biofeedback tool will be employed in which individuals will breathe at their resonance frequency to optimize HRV and autonomic nervous system signatures. | Behavioral: HRV biofeedback<br>* An HRV biofeedback tool will be employed and utilized by individuals each day for the first 5 weeks during the intervention period.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Irritable Bowel Syndrome Symptom Severity Scale Score | Clinical symptom improvement: Improvement in a clinical symptom score. Responders will be classified as those with an Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS; full scale range 0-500, where severe symptoms are ≥ 300) that decreases by ≥ 50 points at the end of week 5. | at end of Week 5 |
Contact Registry for Clinical Trials

Study Overview
=================
Brief Summary
-----------------
The purpose of the Contact Registry for Clinical Trials is to develop a database/listserv of persons interested in clinical trials occurring at the University of Central Florida College of Medicine. Sign up for the UCF College of Medicine's Contact Registry for Clinical Trials to learn about clinical research and clinical trials in areas of interest to you! https://ucf.qualtrics.com/jfe/form/SV_do4WGvKlz4f8Wwe

Detailed Description
-----------------
The Contact Registry for Clinical Trials allow persons to sign up to learn more about clinical trials and clinical research around certain medical indications that will be occurring at the University of Central Florida College of Medicine. Persons are not asked to provide any personal health information. Persons are asked to provide identifying information needed to provide the requested information.

Official Title
-----------------
Contact Registry for Clinical Trials at the University of Central Florida College of Medicine

Conditions
-----------------
This is the Contact Registry

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Persons who do not read English could register through the assistance of their friends or software for translation Exclusion Criteria: Children may not register Persons who are unable to consent may not register

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| This registry will not target any specific populations<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To allow persons to sign up to learn more about clinical trials and clinical research around certain medical indications that will be occurring at the University of Central Florida College of Medicine |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy
Examining Patterns in the Involvement of Gastric Bypass Patients in Clinical Studies

Study Overview
=================
Brief Summary
-----------------
Clinical trial participation has historically been heavily biased toward specific demographics. Several people will be invited to enroll in this study so that it may collect a variety of data about gastric bypass clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. The information collected from this study can be used to improve patient experience and outcomes for future patients and an opportunity to contribute to the advancement of medical knowledge and treatments for gastric bypass.

Official Title
-----------------
An Observational Study Investigating The Experiences of Patients In Gastric Bypass Clinical Trials

Conditions
-----------------
Gastric Bypass, Weight Loss Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years and older Diagnosis of obesity or disorder of metabolism undergoing routine gastric bypass surgical intervention Capable of giving signed informed consent. Exclusion Criteria: ECOG score of 4 Ineligible for gastric bypass surgery Pregnant women or women actively seeking to become pregnant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to participate in a gastric bypass clinical study |  | 3 months | 
| Rate of gastric bypass patients who remain until trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gastric bypass, weight loss surgery
PedBot Ankle Rehablitation

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to determine engagement with use and adherence to a home exercise program with our PedBotHome ankle rehabilitation device. We will place the device in the home for 90 days and consider the study a success if used for at least 30 minutes a day for at least 3 days a week during this period.

Detailed Description
-----------------
The major secondary objective is to determine if the range of motion of the ankle has improved through use of PedBotHome. Other secondary objectives will measure ankle strength and control. Secondary outcomes will include a measurable increase in range of motion across the ankle joint (in any direction) and a measurable increase in strength in plantarflexion, dorsiflexion, inversion, and eversion. Improvement in gait and speed of ambulation will also be considered secondary outcome measures as an indication of better ankle control.

Official Title
-----------------
PedBot Ankle Rehabilitation

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Device: ankle robot


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cerebral palsy Exclusion Criteria: Healthy volunteers

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ankle robot|home ankle robot and video game|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of days used | integer | 90 days |
Skin Disease in Methamphetamine Abuse

Study Overview
=================
Brief Summary
-----------------
1. To detect the skin diseases in patients using methamphetamine

Detailed Description
-----------------
Methamphetamine is a stimulant drug that associated with a broad spectrum of health conditions, include addiction, mental health disorders, and overdose. The Drug Enforcement Agency (DEA) classifies it as a Schedule II drug. This means that the drug has a high potential for misuse. The drug is also called crystal meth, ice, and blue. Methamphetamine use has increased in Egypt especially in upper Egypt. Literature on cutaneous manifestations among methamphetamine users is limited, although cellulitis, delusion of parasitosis (DOP), hyperhidrosis, formication and prurigo nodularis (PN) have been attributed to methamphetamine users. While the relationship between skin lesions and substance use in not fully defined, there is some evidence that points to the development of these itchy, red lesion also known as meth sore after meth use. Meth sores often look like small round red patches on your skin, they can often be confused with acne when they appear on the face or a rash when they appear on other parts of the body. Meth sores form as a result of heavy meth misuse. other signs of meth abuse at the stage where sores likely to develop include: Weight loss Paranoia Hallucinations Aggressive behavior Being easily distracted Tooth and gum decay Changes in brain structure

Official Title
-----------------
Skin Disorders in Patients Using Methamphetamine

Conditions
-----------------
Methamphetamine Abuse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients using methamphetamine Exclusion Criteria: 1. Pregnant and lactating patients. 2. Patients with chronic diseases

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| skin disorders in patients using methamphetamine | questionnaire-based study To detect the skin diseases and manifestation appears in patients using methamphetamine | baseline |
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Study Overview
=================
Brief Summary
-----------------
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Official Title
-----------------
Long-Term Follow-Up of Subjects Treated With NTLA-2001

Conditions
-----------------
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received. A subject has provided informed consent for the LTFU study. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Treatment-related SAEs and Protocol-specified AESIs | Long-term safety assessment of any treatment-related SAEs and protocol-specified AESIs | up to 15 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PD biomarkers for ATTR including serum TTR and serum prealbumin | Long-term assessment of serum TTR and serum prealbumin | up to 15 years |
Prospective Validation of an Acute Pulmonary Embolism Severity and Prognosis Prediction Model

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to prospectively validate the first PUMCH model for acute PE severity and prognosis prediction based on multi-center data constructed in the pre-project period based on national population data, and to optimize the PUMCH model based on artificial intelligence clustering algorithm.

Detailed Description
-----------------
Patients with pulmonary embolism and aged 18 years or older were enrolled in this study.Patient demographic characteristics(age, sex, department, diagnosis), basic vital signs, symptoms at their admissions (hemoptysis, dyspnea, chest pain, syncope, laboratory examinations (blood lab routines, blood gas, liver and kidney function, myocardial marker), and imaging examinations (vascular ultrasonography, computed tomographic angiography, echocardiography, chest CT,CTPA, pulmonary perfusion imaging, pulmonary angiography, PET/CT) were prospectively collected. Patients were followed up every 1/3/6 months to obtain survival outcomes.

Official Title
-----------------
Multicenter Prospective Validation and Extension of the 'PUMCH' Acute Pulmonary Embolism Severity and Prognosis Prediction Model

Conditions
-----------------
Pulmonary Embolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 18 years Inpatients with acute PTE diagnosed by imaging (CTPA, enhanced CT, V/Q imaging suggesting a high probability of PE, pulmonary angiography, MRPA) containing any of the following conditions. primary acute PTE combined with or without DVT recurrent acute PTE with a history of previous PTE or DVT signed informed consent form Exclusion Criteria: blinded to any diagnostic or therapeutic test (VTE or other conditions) unable to complete follow-up (due to cognitive or behavioral limitations, etc.)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | all-cause mortality 30 days after diagnosis of acute symptomatic PE. | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary Embolism, Prognosis assessment model
Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The primary endpoint of this study is the completion time of hemostasis treatment when administered Fresh frozen plasma (FFP) and frozen powder coagulation factor concentrate (PCC) in goal-directed bleeding management for cardiac surgery.

Official Title
-----------------
Prothrombin Complex Concentrate and Fresh Frozen Plasma in Viscoelastic Test-based Goal-directed Bleeding Management in Cardiac Surgery

Conditions
-----------------
Cardiac Valve Disease

Intervention / Treatment
-----------------
* Biological: fresh frozen plasma
* Biological: prothrombin complex concentrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing cardiac surgery Exclusion Criteria: thrombocytopenia oral anti-coagulant anti platelet agents

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Patients are randomly divided into two groups (experimental vs control groups).
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: fresh frozen plasma<br>according to the Rotational thromboelastometry (ROTEM) test, CT-EXTEM prolongation, fresh frozen plasma transfusion (FFP) is performed | Biological: fresh frozen plasma<br>* transfusion of fresh frozen plasma<br>|
| Experimental: prothrombin complex concentrate<br>according to the Rotational thromboelastometry (ROTEM) test, CT-EXTEM prolongation, prothrombin complex concentrate (PCC) is administered | Biological: prothrombin complex concentrate<br>* prothrombin complex concentrate administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment time | duration from the time diagnosing CT-EXTEM prolongation to the time achieving bleeding control | 1 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Red Blood Cell amount | Red Blood Cell transfusion amount during surgery | I hour | 
| FFP amount | Red Blood Cell transfusion amount during surgery | 1 hour | 
| Platelet amount | Platelet transfusion amount during surgery | 1 hour | 
| CT-EXTEM | clotting time-EXTEM after PCC or FFP | 10 min | 
| MA-EXTEM | Maximal amplitude-EXTEM after PCC or FFP | 10 min | 
| MA-FIBTEM | Maximal amplitude-FIBTEM after PCC or FFP | 10 min | 
| Postoperative bleeding | chest tube drainage at postoperative 24 hour | 24 hour |
Feasibility of Brachial Plexus Ultrasound in Evaluation of Patients With Brachial Plexus Injuries

Study Overview
=================
Brief Summary
-----------------
Evaluation of ultrasound as a diagnostic tool in assessment of patients with brachial plexus injuries before undergoing surgical exploration

Detailed Description
-----------------
Ultrasound of the brachial plexus is particularly good for assessing brachial plexus injuries, nerve sheath tumors,perineural fibrosis, metastasis, some inflammatory neuropathies, neuralgic amyotrophy and post traumatic sequele

Official Title
-----------------
Feasibility of Brachial Plexus Ultrasound in Evaluation of Patients With Brachial Plexus Injuries

Conditions
-----------------
Brachial Plexus Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients ages with brachial plexus injuries Exclusion Criteria: patients underwent brachial plexus surgery before patients with surgical emphysema patients with serious skeletal malformations
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with positive ultrasound findings of brachial plexus injuries ( nerve root avulsion, nerve rupture) . | Number of patients with positive ultrasound findings of brachial plexus injuries ( nerve root avulsion, nerve rupture) among all patients with brachial plexus injuries then compare our results with operative findings (as the gold standard ) to estimate sensitivity and specificity. | Within 2 weeks |